thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Technology
  • entertainment
  • Sports
  • Business
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Technology
  • entertainment
  • Sports
  • Business
Follow US
© thenewsfacts : All Rights Reserved.

Home » New Study says SARS-CoV-2 Vaccine generated immunity will last longer

COVID-19

New Study says SARS-CoV-2 Vaccine generated immunity will last longer

TheNewsFacts
Last updated: July 2, 2021 11:37 am
TheNewsFacts
Share
New Study says SARS-CoV-2 Vaccine generated immunity will last longer
SHARE

A new study conducted in Barcelona reported that one year after infection by SARS-CoV-2, most people maintain anti-Spike antibodies regardless of the severity of their symptoms, according to a study with healthcare workers co-led by the Barcelona Institute for Global Health (ISGlobal), the Catalan Health Institute (ICS) and the Jordi Gol Institute (IDIAP JG), with the collaboration of the Daniel Bravo Andreu Private Foundation.

The results suggest that vaccine-generated immunity will also be long-lasting.

The research team took regular blood samples from September 2020 onwards to measure the level and type of SARS-CoV-2-specific antibodies in these patients. This work was possible thanks to the support of the Daniel Bravo Foundation, which equipped ISGlobal with the latest technology and necessary resources to perform the study and rapidly reach conclusions during the subsequent waves.

One of the key questions to better predict the pandemic’s evolution is the duration of natural immunity. A growing number of studies suggest that most people generate a humoral (antibody) and cellular (T cells) response that is maintained during several months, maybe years.

During the first wave of the pandemic, the team at ICS/IDIAP JG in collaboration with Carlota Dobaño’s team at ISGlobal started a follow-up study of a cohort of healthcare workers with COVID-19 – a total of 173 people working in healthcare centers of central Catalonia. Most infections were mild to moderate, although some cases required hospitalization.

According to the study , No significant decay in antibody levels was observed over the first five months, and at 9 months, 92.4% of peoples remained seropositive – 90% of them had IgG, 76% had IgA and 61% had IgM recognising the Spike protein or the receptor binding domain (RBD). The results were similar among healthcare workers who had not been vaccinated in April (95% had IgG, 83% IgA and 25% IgM).

“These data confirm that IgG have a longer duration, but IgM levels, which are supposed to last less, were unexpectedly quite sustained over time,” says Gemma Moncunill, ISGlobal researcher and senior co-author of the study, together with Ruíz-Comellas. Hospitalization, fever, and loss of smell and taste were associated with higher antibody levels at five or nine months.

Share This Article
Email Copy Link Print
Previous Article Global Tax Reforms to become a reality soon Global Tax Reforms to become a reality soon
Next Article Wimbledon 2021 to advocate going green to the world Wimbledon 2021 to advocate going green to the world

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
XFollow
InstagramFollow

Popular Posts

Charlie Munger, a Buffet of Inspiration Beyond Numbers, is No More

Renowned investor Charlie Munger, whose wisdom and astute investment strategies helped shape the success of…

By
TheNewsFacts

Despite Crash Ferrari’s Charles Leclerc takes pole in the last-lap

Charles Leclerc, Formula One Driver on Saturday took a sensational pole position in the Monaco…

By
TheNewsFacts

Djokovic not playing US Open is a joke – McEnroe

Novak Djokovic said he will miss the US Open which begins on Monday as Covid…

By
TheNewsFacts

You Might Also Like

If a family member gets sick? What to do?
COVID-19

If a family member gets sick? What to do?

By
TheNewsFacts
COVAXIN Maker Bharat Biotech Intranasal Vaccine (BBV154) Approved for Phase 3 Clinical Trials
COVID Vaccines

COVAXIN Maker Bharat Biotech Intranasal Vaccine (BBV154) Approved for Phase 3 Clinical Trials

By
TheNewsFacts

COVID-19 third wave prevention is a priority now – PM Modi

By
TheNewsFacts
Big spike in Delta Variant cases in the US due to Vaccine Hesitancy
COVID-19

Big spike in Delta Variant cases in the US due to Vaccine Hesitancy

By
TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?